LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ:AMEX Investor Relations:
lixte.com/investor_information_02.php
Company Research
Source: GlobeNewswire
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company’s Liora Technologies Europe Ltd. subsidiary (“Liora”). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE’s acquisition of Liora’s assets in November 2025 from Orbit Capital, Inc. Over his career, Braun played a key role in building an infusion network for the biologic drug Remicade, which was approved to treat several immune-mediated inflammatory diseases. He also created a physician network in Canada that was sold to Toronto-based AIM Health Group. Braun is multi-lingual and holds
Show less
Read more
Impact Snapshot
Event Time:
LIXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIXT alerts
High impacting Lixte Biotechnology Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
LIXT
News
- LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape [Yahoo! Finance]Yahoo! Finance
- Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care ConferenceGlobeNewswire
- MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year [TheStreet.com]TheStreet.com
- LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes [TheStreet.com]TheStreet.com
- LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative YearGlobeNewswire
LIXT
Sec Filings
- 4/17/26 - Form 4
- 4/17/26 - Form 4
- 4/17/26 - Form 4
- LIXT's page on the SEC website